Cancer Management and Research (Dec 2021)
Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients
Abstract
Stefanie Hecker-Nolting,1 Thorsten Langer,2 Claudia Blattmann,1 Leo Kager,3 Stefan S Bielack1,4 1Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart – Olgahospital, Stuttgart, Germany; 2Pädiatrische Onkologie und Hämatologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; 3St. Anna Kinderspital, Abteilung für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria; 4Abteilung für Pädiatrische Hämatologie und Onkologie, Klinik für Kinder- und Jugendmedizin – Pädiatrische Hämatologie und Onkologie, Münster, GermanyCorrespondence: Stefan S BielackPädiatrie 5 (Onkologie, Hämatologie, Immunologie) Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart – Olgahospital, Kriegsbergstr. 62, Stuttgart, 70174, GermanyTel +49 711 2787 3881Fax +49 711 2787-3882Email [email protected]: With ever increasing long-term, disease free survival rates, long-term toxicities of otherwise successful therapy have gained increasing importance. They can be grouped into potentially life-threatening, especially secondary malignancies and anthracycline cardiomyopathies, potentially disabling, particularly severe hearing loss and renal insufficiency, other, and rare events. Pathophysiology, frequency, and medical treatment approaches are discussed. Finally, fertility issues and quality of life issues are discussed, together with an outlook into the future. The challenge to cure as many patients as possible from osteosarcoma while enabling a life free of late effects will remain.Keywords: osteosarcoma, child, adolescent, chemotherapy, late effects
